title: Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data.
abstract: OBJECTIVE
  To use preclinical and clinical pharmacokinetic (PK)/pharmacodynamic (PD) modeling to predict optimal clinical regimens of everolimus, a novel oral mammalian target of rapamycin (mTOR) inhibitor, to carry forward to expanded phase I with tumor biopsy studies in cancer patients.
  
  
  METHODS
  Inhibition of S6 kinase 1 (S6K1), a molecular marker of mTOR signaling, was selected for PD analysis in peripheral blood mononuclear cells (PBMCs) in a phase I clinical trial. PK and PD were measured up to 11 days after the fourth weekly dose. A PK/PD model was used to describe the relationship between everolimus concentrations and S6K1 inhibition in PBMCs of cancer patients and in PBMCs and tumors of everolimus-treated CA20948 pancreatic tumor-bearing rats.
  
  
  RESULTS
  Time- and dose-dependent S6K1 inhibition was demonstrated in human PBMCs. In the rat model, a relationship was shown between S6K1 inhibition in tumors or PBMCs and antitumor effect. This allowed development of a direct-link PK/PD model that predicted PBMC S6K1 inhibition-time profiles in patients. Comparison of rat and human profiles simulated by the model suggested that a weekly 20- to 30-mg dose of everolimus would be associated with an antitumor effect in an everolimus-sensitive tumor and that daily administration would exert a greater effect than weekly administration at higher doses.
  
  
  CONCLUSIONS
  A direct-link PK/PD model predicting the time course of S6K1 inhibition during weekly and daily everolimus administration allowed extrapolation from preclinical studies and first clinical results to select optimal doses and regimens of everolimus to explore in future clinical trials.
authors.affiliation: Novartis Pharmaceuticals Corp, East Hanover, NJ, USA.
authors.forename: Chiaki
authors.initials: C
authors.lastname: Tanaka
authors.forename: Terence
authors.initials: T
authors.lastname: O'Reilly
authors.forename: John M
authors.initials: JM
authors.lastname: Kovarik
authors.forename: Nicholas
authors.initials: N
authors.lastname: Shand
authors.forename: Katharine
authors.initials: K
authors.lastname: Hazell
authors.forename: Ian
authors.initials: I
authors.lastname: Judson
authors.forename: Eric
authors.initials: E
authors.lastname: Raymond
authors.forename: Sabine
authors.initials: S
authors.lastname: Zumstein-Mecker
authors.forename: Christine
authors.initials: C
authors.lastname: Stephan
authors.forename: Anne
authors.initials: A
authors.lastname: Boulay
authors.forename: Marc
authors.initials: M
authors.lastname: Hattenberger
authors.forename: George
authors.initials: G
authors.lastname: Thomas
authors.forename: Heidi A
authors.initials: HA
authors.lastname: Lane
mesh_terms: D000818:Animals; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D000068338:Everolimus; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008954:Models, Biological; D009369:Neoplasms / Q000188:drug therapy*; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000378:metabolism; D051381:Rats; D038762:Ribosomal Protein S6 Kinases, 70-kDa / Q000037:antagonists & inhibitors*; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology
chemical_list: D007166:Immunosuppressive Agents; D000068338:Everolimus; D038762:Ribosomal Protein S6 Kinases, 70-kDa; C448901:ribosomal protein S6 kinase, 70kD, polypeptide 1; D020123:Sirolimus